TAT (drugs) | N° patients (%) |
---|---|
Alemtuzumab | 1 (0.19) |
Bevacizumab | 110 (20.52) |
Cetuximab | 80 (14.93) |
Ipilimumab | 4 (0.75) |
Panitumumab | 5 (0.93) |
Rituximab | 76 (14.18) |
Trastuzumab | 104 (19.48) |
Dasatinib | 10 (1.86) |
Erlotinib | 49 (9.14) |
Gefitinib | 6 (1.12) |
Imatinib | 53 (9.90) |
Lapatinib | 20 (3.73) |
Nilotinib | 6 (1.12) |
Sorafenib | 8 (1.49) |
Sunitinib | 22 (4.10) |
Bortezomib | 15 (2.80) |